ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Premium IconPremium Help Menu
S&P 500
6,033.11
0.94%
US Tech 100
21,286.40
0.99%
Dow Jones
42,515.09
0.75%
Brent Oil
71.76
-4.15%
Bitcoin
107,925.42
2.24%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. IGM Biosciences Inc (IGMS) Quote

IGM Biosciences Inc

IGM Biosciences Inc (IGMS)

NASDAQ
1.22
0.01
(0.83%)
At close: June 16 4:00PM
15 min delayed - Upgrade to Realtime
1.22
0.00
( 0.00% )
After Hours: 4:56PM
15 min delayed - Upgrade to Realtime

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
1.22
Bid
1.17
Ask
1.26
Volume
127,729
1.17 Day's Range 1.23
0.92 52 Week Range 22.50
Market Cap
73.34M
Previous Close
1.21
Open
1.20
Last Trade
8
@
1.1704
Last Trade Time
18:52:39
Financial Volume
$ 154,312
VWAP
1.2081
Average Volume (3m)
177,217
Shares Outstanding
60,115,076
Dividend Yield
-
PE Ratio
-0.37
Earnings Per Share (EPS)
-3.26
Revenue
2.68M
Net Profit
-195.8M

About IGM Biosciences Inc

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking ago... IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.igmbio.com
Headquarters
Dover, Delaware, USA
Founded
-
IGM Biosciences Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IGMS. The last closing price for IGM Biosciences was $1.21. Over the last year, IGM Biosciences shares have traded in a share price range of $ 0.92 to $ 22.50.

IGM Biosciences currently has 60,115,076 shares outstanding. The market capitalization of IGM Biosciences is $72.74 million. IGM Biosciences has a price to earnings ratio (PE ratio) of -0.37.

Ask ADVFN Intelligence (AI)

IGMS Latest News

More News

Form 8-K - Current report
Edgar (US Regulatory)
June 11 2025
IGMS (0.83%)

Form 8-K - Current report
Edgar (US Regulatory)
May 29 2025
IGMS (0.83%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
May 13 2025
IGMS (0.83%)

Form 8-K - Current report
Edgar (US Regulatory)
May 08 2025
IGMS (0.83%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
April 02 2025
IGMS (0.83%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
April 02 2025
IGMS (0.83%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
April 02 2025
IGMS (0.83%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
April 02 2025
IGMS (0.83%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
March 18 2025
IGMS (0.83%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
March 18 2025
IGMS (0.83%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.09-6.870229007631.311.41.192110251.2849857CS
40.021.666666666671.21.421.132171541.27268614CS
120.021.666666666671.21.470.921772171.2423846CS
26-5.82-82.67045454557.047.860.923193902.09220057CS
52-5.91-82.8892005617.1322.50.923035816.94087826CS
156-12.65-91.20403749113.8728.20.9228112110.61469004CS
260-65.27-98.165137614766.491330.9230313426.27581221CS

IGMS - Frequently Asked Questions (FAQ)

What is the current IGM Biosciences share price?
The current share price of IGM Biosciences is $ 1.22
How many IGM Biosciences shares are in issue?
IGM Biosciences has 60,115,076 shares in issue
What is the market cap of IGM Biosciences?
The market capitalisation of IGM Biosciences is USD 72.74M
What is the 1 year trading range for IGM Biosciences share price?
IGM Biosciences has traded in the range of $ 0.92 to $ 22.50 during the past year
What is the PE ratio of IGM Biosciences?
The price to earnings ratio of IGM Biosciences is -0.37
What is the cash to sales ratio of IGM Biosciences?
The cash to sales ratio of IGM Biosciences is 27.35
What is the reporting currency for IGM Biosciences?
IGM Biosciences reports financial results in USD
What is the latest annual turnover for IGM Biosciences?
The latest annual turnover of IGM Biosciences is USD 2.68M
What is the latest annual profit for IGM Biosciences?
The latest annual profit of IGM Biosciences is USD -195.8M
What is the registered address of IGM Biosciences?
The registered address for IGM Biosciences is CORPORATION TRUST CENTER, 1209 ORANGE ST, DOVER, DELAWARE, 19901
What is the IGM Biosciences website address?
The website address for IGM Biosciences is www.igmbio.com
Which industry sector does IGM Biosciences operate in?
IGM Biosciences operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
JZJianzhi Education Technology Group Company Ltd
$ 5.21
(82.17%)
2.94M
LGHLWLion Group Holding Ltd
$ 0.005
(66.67%)
57.2k
SLRXSalarius Pharmaceuticals Inc
$ 1.02
(63.17%)
10.55M
INEOINNEOVA Holdings Ltd
$ 1.61
(45.05%)
4.13M
RELIReliance Global Group Inc
$ 1.60
(35.59%)
3.5M
RUNSunrun Inc
$ 7.24
(-24.90%)
4.2M
SEDGSolarEdge Technologies Inc
$ 18.96
(-20.93%)
677.1k
CDTGCDT Environmental Technology Investment Holdings Ltd
$ 1.15
(-16.14%)
244.18k
ENPHEnphase Energy Inc
$ 38.60
(-15.96%)
808.27k
AGYSAgilysys Inc
$ 95.0125
(-13.59%)
1.75k
GNLNGreenlane Holdings Inc
$ 0.0119
(-4.03%)
49.17M
GTIGraphjet Technology
$ 0.0789
(3.00%)
40.01M
HCTIHealthcare Triangle Inc
$ 0.0253
(-4.17%)
35.24M
SLRXSalarius Pharmaceuticals Inc
$ 1.02
(63.17%)
10.55M
TDTHTrident Digital Tech Holdings Ltd
$ 0.275
(12.47%)
9.07M

IGMS Discussion

View Posts
Monksdream Monksdream 1 month ago
IGMS under $2
👍️0
Monksdream Monksdream 2 months ago
IGMS under $2
👍️0
Monksdream Monksdream 2 months ago
IGMS, under $2
👍️0
Monksdream Monksdream 11 months ago
IGMS under $10
👍️0
Monksdream Monksdream 1 year ago
IGMS under $10
👍️0
crudeoil24 crudeoil24 3 years ago
Truist Reiterates Buy Rating, $80 Price Target.
👍️0
crudeoil24 crudeoil24 3 years ago
Let's see if IGMS gets FDA phase I,II,III, approvals . Sanofi believes it'll happen.
👍️0
crudeoil24 crudeoil24 3 years ago
14M float!
👍️0
crudeoil24 crudeoil24 3 years ago
Tons of cash going forward > IGM Biosciences, Inc. (NASDAQ: IGMS) today announced that it intends to offer and sell $200.0 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, non-voting common stock, in an underwritten public offering. In addition, IGM intends to grant the underwriters a 30-day option to purchase up to an additional $30.0 million of shares at the public offering price, less underwriting discounts and commissions. All of the securities offered in the offering will be sold by IGM. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
J.P. Morgan, BofA Securities, Stifel, and Guggenheim Securities are acting as joint book-running managers for the offering.
👍️0
TheFinalCD TheFinalCD 3 years ago
https://ih.advfn.com/stock-market/NASDAQ/igm-biosciences-IGMS/stock-news/87682546/igm-announces-proposed-public-offering

https://www.wsgr.com/print/v2/content/185066/Firm-Advises-IGM-Biosciences%2C-Inc.-on-%24230-Million-Public-Offering.pdf
👍️0

Your Recent History

NASDAQ
IGMS
IGM Biosciences
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub
United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN Ltd - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads